EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit

NEW YORK , Oct. 17, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024 , both dates inclusive (the "Class Period"). A class action has already been filed.

If you wish to serve as lead plaintiff, you must move the Court no later than December 13, 2024 . So what: If you purchased Edwards Lifesciences Corporation securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Edwards Lifesciences Corporation class action, go to https://rosenlegal.



com/submit-form/?case_id=29704 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 13 , 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Details of the case: According to the lawsuit, during the Class Period, defendants provided investors with material information concerning Edwards' expected revenue for the fiscal year 2024, particularly as it related to the growth of Edwards' core product, Transcatheter Aortic Valve Replacement ("TAVR"). Defendants' statements included, among other things, strong commitment to the TAVR platform, confidence in Edwards' ability to capitalize on a subset of untreated patients through scaling of its various patient activation activities, and continued claims of significant demand in allegedly lower-penetrated markets. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Edwards class action, go to https://rosenlegal.com/submit-form/?case_id=29704 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.

com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one.

You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.

com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ .

Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq.

Phillip Kim, Esq. The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.

com View original content to download multimedia: https://www.prnewswire.com/news-releases/ew-investors-have-opportunity-to-lead-edwards-lifesciences-corporation-securities-fraud-lawsuit-302279877.

html SOURCE THE ROSEN LAW FIRM, P. A..